14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today CLSN ranks #16791 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

Celsion Corporation Stock Forecast NASDAQ:CLSN

$0.68 (-4.90%)

Volume: 623k

Closed: Dec 03, 2021

Hollow Logo Score: -6.239

Celsion Corporation Stock Forecast

$0.68 (-4.90%)

Volume: 623k

Closed: Dec 03, 2021

Score Hollow Logo -6.239
Which way will CLSN go? Request
Key Stats
P/E Ratio -3.01
Beta 1.33
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
RSImin/max Values: [ 20 - 75 ] RSI14 is 30 and the stock is currently not being overbought or oversold

Celsion Corporation stock downgraded from Sell Candidate to Strong Sell Candidate after Friday trading session.
(Updated on Dec 03, 2021)

Sell candidate since 2021-11-02 Loss -26.57%

The Celsion Corporation stock price fell by -4.90% on the last day (Friday, 3rd Dec 2021) from $0.72 to $0.68. and has now fallen 5 days in a row. During the day the stock fluctuated 8.94% from a day low at $0.67 to a day high of $0.73. The price has fallen in 8 of the last 10 days and is down by -9.83% for this period. Volume has increased on the last day by 25 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 623 thousand shares were bought and sold for approximately $423.89 thousand.

The stock lies in the lower of a very wide and falling trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $0.67 is broken, it will firstly indicate a stronger fall rate. Given the current short-term trend, the stock is expected to fall -27.48% during the next 3 months and, with a 90% probability hold a price between $0.48 and $0.62 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Signals & Forecast

There are few to no technical positive signals at the moment. The Celsion Corporation stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $0.73 and $0.85. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Wednesday, October 13, 2021, and so far it has fallen -35.24%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Celsion Corporation gained volume on the last day, but on falling prices. In technical terms, this is called divergence and may be an early warning. In some cases, increasing volume on falling prices may be considered positive, but that is mainly in typical "sell-offs".

Support, Risk & Stop-loss

There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.

This stock may move much during the day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $0.0599 between high and low, or 8.94%. For the last week, the stock has had a daily average volatility of 7.56%.

Our recommended stop-loss: We hold an negative evaluation for this stock. No stop-loss is set.

Is Celsion Corporation stock A Buy?

Celsion Corporation holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Sell to a Strong Sell candidate.

Current score: -6.239

Predicted Opening Price for Celsion Corporation of Monday, December 6, 2021

The predicted opening price is based on yesterday's movements between high, low, and the closing price.

Fair opening price December 6, 2021 Current price
$0.69 $0.68 (Undervalued)
Strong Sell Candidate Downgraded

Remember To Visit Our YouTube Channel

Analyst Ratings

Dawson James is very positive about CLSN and gave it a "Buy" rating on Jun 24, 2020. The price target was set to $4.00.

Volatility and Risk
Daily Average Volatility: 7.56 %
Overall Risk: Very High High Medium Low Very Low
7.56 %
Daily Average Volatility
Overall Risk

Very High
Very Low

Support & Resistance

Resistance: $0.76
Price: $0.68
No Support Found

CLSN Insider Trading Show all Trades



Last 100 transactions
Buy: 4 388 450 | Sell: 1 490 000 (Shares)
Date Action Amount Person Type
Oct 07, 2021 Buy 20 000 Fritz Frederick J. Celsion Corporation Common Stock
Jun 08, 2021 Buy 40 000 Pellizzari Christine A Option to Purchase Celsion Corporation Common Stock
Jun 04, 2021 Buy 40 000 Lindborg Stacy Option to Purchase Celsion Corporation Common Stock
May 17, 2021 Buy 5 000 Braun Donald P Celsion Corporation Common Stock
Mar 19, 2021 Buy 40 000 Chow Pok Yu Augustine Option to Purchase Celsion Corporation Common Stock
Show all Insider Trades


Last 100 transactions
Buy: 4 388 450 | Sell: 1 490 000 (Shares)

Fibonacci Support & Resistance Levels

Level Price Change
Resistance 0.75 10.76 %
0.73 7.40 %
0.72 5.32 %
Current price: 0.68
Support 0.67 -1.41 %
0.66 -3.49 %
0.63 -6.85 %

Accumulated Volume Support & Resistance Levels

Level Price Chg %
Resistance 0.83 22.51 %
0.80 17.63 %
0.76 11.76 %
Current price 0.68
Support 0 .
0 .
0 .

Click to get the best stock tips daily for free!

About Celsion Corporation

Celsion Celsion Corporation, an oncology drug development company, focuses on the development and commercialization of chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology. The company’s lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials for recurrent chest wall breast cancer. It has a developme... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 100 000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE